InterWest Partners | GenomeWeb

InterWest Partners

Bruker said this week it has appointed Joshua Young vice president of investor relations. Young will take over from Stacey Desrochers, who will focus on management of the company's treasury operations.

The company next year plans to launch a 1,000-patient verification trial for its lung cancer protein biomarker panel, with trials for its Alzheimer's disease panel likely to follow, said an official.

The molecular diagnostics company plans to use the funds for marketing and R&D.

Lycera, which is developing drugs for autoimmune diseases, will use the cash to advance through Phase II proof-of-concept studies a drug based on University of Michigan research, and into Phase I trials a second candidate based on research conducted at New York University.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.